Cargando…

Collateral activity of the CRISPR/RfxCas13d system in human cells

CRISPR/Cas13 systems are increasingly used for programmable targeting of RNAs. While Cas13 nucleases are capable of degrading both target RNAs and bystander RNAs in vitro and in bacteria, initial studies fail to detect collateral degradation of non-target RNAs in eukaryotic cells. Here we show that...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Peiguo, Murphy, Michael R., Aparicio, Alexis O., Kesner, Jordan S., Fang, Zhou, Chen, Ziheng, Trehan, Aditi, Guo, Yang, Wu, Xuebing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049998/
https://www.ncbi.nlm.nih.gov/pubmed/36977923
http://dx.doi.org/10.1038/s42003-023-04708-2
_version_ 1785014583702847488
author Shi, Peiguo
Murphy, Michael R.
Aparicio, Alexis O.
Kesner, Jordan S.
Fang, Zhou
Chen, Ziheng
Trehan, Aditi
Guo, Yang
Wu, Xuebing
author_facet Shi, Peiguo
Murphy, Michael R.
Aparicio, Alexis O.
Kesner, Jordan S.
Fang, Zhou
Chen, Ziheng
Trehan, Aditi
Guo, Yang
Wu, Xuebing
author_sort Shi, Peiguo
collection PubMed
description CRISPR/Cas13 systems are increasingly used for programmable targeting of RNAs. While Cas13 nucleases are capable of degrading both target RNAs and bystander RNAs in vitro and in bacteria, initial studies fail to detect collateral degradation of non-target RNAs in eukaryotic cells. Here we show that RfxCas13d, also known as CasRx, a widely used Cas13 system, can cause collateral transcriptome destruction when targeting abundant reporter RNA and endogenous RNAs, resulting in proliferation defect in target cells. While these results call for caution of using RfxCas13d for targeted RNA knockdown, we demonstrated that the collateral activity can be harnessed for selective depletion of a specific cell population defined by a marker RNA in an in vitro setting.
format Online
Article
Text
id pubmed-10049998
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100499982023-03-30 Collateral activity of the CRISPR/RfxCas13d system in human cells Shi, Peiguo Murphy, Michael R. Aparicio, Alexis O. Kesner, Jordan S. Fang, Zhou Chen, Ziheng Trehan, Aditi Guo, Yang Wu, Xuebing Commun Biol Article CRISPR/Cas13 systems are increasingly used for programmable targeting of RNAs. While Cas13 nucleases are capable of degrading both target RNAs and bystander RNAs in vitro and in bacteria, initial studies fail to detect collateral degradation of non-target RNAs in eukaryotic cells. Here we show that RfxCas13d, also known as CasRx, a widely used Cas13 system, can cause collateral transcriptome destruction when targeting abundant reporter RNA and endogenous RNAs, resulting in proliferation defect in target cells. While these results call for caution of using RfxCas13d for targeted RNA knockdown, we demonstrated that the collateral activity can be harnessed for selective depletion of a specific cell population defined by a marker RNA in an in vitro setting. Nature Publishing Group UK 2023-03-28 /pmc/articles/PMC10049998/ /pubmed/36977923 http://dx.doi.org/10.1038/s42003-023-04708-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Shi, Peiguo
Murphy, Michael R.
Aparicio, Alexis O.
Kesner, Jordan S.
Fang, Zhou
Chen, Ziheng
Trehan, Aditi
Guo, Yang
Wu, Xuebing
Collateral activity of the CRISPR/RfxCas13d system in human cells
title Collateral activity of the CRISPR/RfxCas13d system in human cells
title_full Collateral activity of the CRISPR/RfxCas13d system in human cells
title_fullStr Collateral activity of the CRISPR/RfxCas13d system in human cells
title_full_unstemmed Collateral activity of the CRISPR/RfxCas13d system in human cells
title_short Collateral activity of the CRISPR/RfxCas13d system in human cells
title_sort collateral activity of the crispr/rfxcas13d system in human cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049998/
https://www.ncbi.nlm.nih.gov/pubmed/36977923
http://dx.doi.org/10.1038/s42003-023-04708-2
work_keys_str_mv AT shipeiguo collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT murphymichaelr collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT aparicioalexiso collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT kesnerjordans collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT fangzhou collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT chenziheng collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT trehanaditi collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT guoyang collateralactivityofthecrisprrfxcas13dsysteminhumancells
AT wuxuebing collateralactivityofthecrisprrfxcas13dsysteminhumancells